Merional(Merional) - 药物靶点：LHCGR_在研适应症：无排卵_专利_临床

概要

基本信息

药物类型

激素

别名

human menopausal gonadotropin( IBSA Institut Biochimique SA)

靶点

LHCGR

作用机制

LHCGR激动剂(促黄体激素/绒毛膜促性腺激素受体激动剂)

治疗领域

内分泌与代谢疾病泌尿生殖系统疾病

在研适应症

无排卵

非在研适应症

多囊卵巢综合征

原研机构

IBSA Institut Biochimique SA

在研机构

Ibsa Farmaceutici Italia Srl

非在研机构

Saudi German Hospitals Group

最高研发阶段批准上市

首次获批日期

(2009-03-02),

无排卵

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

10

项与 Merional 相关的临床试验

NCT04754243

/ Recruiting临床4期IIT

A Higher Ovulation and Pregnancy Rates in Patients With Unexplained Infertility After Application of ANTIUI Protocol: A Randomized Multicenter Controlled Study

The new protocol ANTIUI provides good results regarding ovulation and pregnancy rates in patients with unexplained infertility

开始日期2021-03-01

申办/合作机构

Tanta University

IRCT20151013024512N7

/ Completed临床2期IIT

A comparison of the effect of intraovarian injection of autologous platelet rich plasma (PRP) versus PRP plus gonadotropin and gonadotropin alone on ovarian rejuvenation in patients with diminished ovarian reserve

开始日期2021-02-15

申办/合作机构-

NCT04537078

/ Completed临床3期IIT

Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders

The worldwide prevalence of primary and secondary infertility is estimated at
2% and 10.5%, respectively, among women aged 20-44 years and attempting to conceive. Poor ovarian responders (PORs) involve 9-24% of patients undergoing in-vitro fertilization (IVF). proper tailoring of the ovarian stimulation protocol in order to maximize the number of oocytes collected represents a crucial step for them to eventually conceive.
Recent evidence indicates that in the same menstrual cycle, there are multiple follicular recruitment waves. This coincides with the theory that folliculogenesis occurs in a wave-like fashion. Thus, within a single menstrual cycle, there can theoretically be multiple opportunities for a clinician to collect oocytes, as opposed to the conventional single cohort of antral follicles during the follicular phase.
Utilizing this concept, clinicians have been attempting to retrieve oocytes from poor responders using both the follicular-phase stimulation (FPS) and the luteal-phase stimulation (LPS) protocols to increase the number of oocytes collected shorter within shorter period of time. By increasing the number of the retrieved oocytes collected, a better clinical can be assured since there is a clear relationship between the number of oocytes collected and live birth rates across all female age groups.
which protocol is the most effective remains controversial and the efficacy of PPOS in POR compared with that of conventional protocols is unclear.

开始日期2020-09-01

申办/合作机构-

100 项与 Merional 相关的临床结果

登录后查看更多信息

100 项与 Merional 相关的转化医学

登录后查看更多信息

100 项与 Merional 相关的专利（医药）

登录后查看更多信息

756

项与 Merional 相关的文献（医药）

2024-12-31·Česká gynekologie

Comparing highly purified human menopausal gonadotropin and recombinant follicle stimulating hormone in poor ovarian reserve patients undergoing intracytoplasmic sperm injection

Article

作者: Tutar, Mahmut Sami ; Akgun, Humeyra ; Gunenc, Oguzhan ; Dogru, Sukran ; Korucu, Dilay Gok

Objective: We aimed to compare highly purified human menopausal gonadotropin (hp-hMG) and recombinant follicle stimulating hormone (rFSH) in short antagonist in vitro fertilization (IVF) cycles of patients with poor ovarian reserve (POR). Limited research exists on this comparison in short antagonist cycles for this patient group. Materials and methods: This retrospective cohort study involved 165 POR patients aged 18–45 years who underwent IVF between 2018 and 2022. Patients were divided into two groups based on their GnRH antagonist protocol: hp-hMG (group 1 = 72) and rFSH (group 2 = 93). We compared pregnancy outcomes, number of oocytes collected, mature oocytes retrieved, mean fertilized oocytes, top quality embryos transferred, and serum estradiol (E2) and progesterone (P) levels on human chorionic gonadotropin (hCG) administration day. Results: No significant differences were found in E2 and P levels on hCG trigger day, endometrial thickness on transfer day, stimulation duration, total oocyte number, and mature oocyte number (P > 0.05). The total gonadotropin dose was significantly higher in the rFSH group (P < 0.001). The number of top-quality embryos transferred and clinical pregnancy and live birth rates did not diff er significantly between groups (P = 0.320; P = 0.310; P = 0.652; and P = 0.662, resp.). Conclusion: Neither hp-hMG nor rFSH showed superiority in patients with POR, indicating similar effectiveness in this population. Key words: highly purified human menopausal gonadotropin – in vitro fertilization – live birth – poor ovarian reserve – recombinant follicle stimulating hormone

2024-12-01·Iranian biomedical journal

25th National and 11th International Annual Congress on Research and Technology of Iranian Medical Sciences Students, Urmia, Iran, 5-7 September, 2024

Article

作者: Khadem Ghaebi, Nayyereh ; Joghatayi, Farzaneh ; Morovatdar, Negar ; Afiat, Maliheh ; Afzaljavan, Fahimeh ; Pousti, Navid

IntroductionInfertility is a severe challenge for most health systems. One of the medications recently used for ovulation induction is letrozole, applied either alone or in combination with gonadotropin. The present study was conducted to compare ovulation induction in infertile polycystic ovarian syndrome (PCOS) women candidates of intrauterine insemination (IUI) who were resistant to letrozole by two regimens: single-drug stair step letrozole vs. combined letrozole plus human menopausal gonadotropin.Methods and MaterialsIn this parallel randomized clinical trial, 60 infertile women with PCOS, candidates for intrauterine insemination, admitted to Milad Infertility Center at Imam Reza Hospital, Mashhad, Iran, were randomly assigned into two groups. The intervention group received 5 mg of letrozole for five days from menstruation day 3 and 7.5 mg of letrozole for another five days if dominant follicles were not observed on days 14-19. Control cases received letrozole (5 mg) from day 3 of the cycle for five days plus Cinnal-f® (75 international units subcutaneously daily) on days 8 and 9. They received another dose of Cinnal-f® if the dominant follicle was not observed on days 10-12 of the cycle. In the case of detecting dominant follicles, 5000 units of intramuscular hCG were prescribed, and 36 hours later, the patients underwent IUI. The outcomes were considered, and data were analyzed using SPSS.ResultsAlmost 70% of the stair-step letrozole group and 53.2% in the combined medication had a dominant follicle (p = 0.12), mainly observed after day 14 in the stair-step letrozole group and during days 10-14 in the letrozole/gonadotropin group (p = 0.001). The positive beta-hCG level was significantly higher in the stair-step letrozole group (23.3%) than in the letrozole/gonadotropin group (13.3%). The clinical pregnancy and gestations of 20 weeks or beyond (ongoing pregnancy) were 16.66% and 10% in the stair-step letrozole and letrozole/gonadotropin groups, respectively (p = 0.03).Conclusion and DiscussionOur study found similar frequencies of dominant follicles between the stair-step letrozole and letrozole/ gonadotropin groups and a significantly higher frequency of chemical pregnancy (positive beta-hCG) and clinical and ongoing pregnancy in the stair-step letrozole group. As an easy and acceptable method for patients, this protocol can be a suitable alternative for ovulation induction.

2024-10-01·Journal of Obstetrics and Gynaecology Research

Luteinizing hormone supplementation with human menopausal gonadotropin versus low dose human chorionic gonadotropin during ovarian stimulation does not affect live birth rates after fresh and frozen embryo transfer

Article

作者: Kim, Sung Tae ; Weinerman, Rachel ; Chung, Rebecca K. ; Fischer, Linnea ; Flyckt, Rebecca

AbstractAimLuteinizing hormone (LH) plays an important role in ovarian follicle maturation. Human menopausal gonadotropin (hMG) or low dose human chorionic gonadotropin (hCG) can provide LH supplementation during in vitro fertilization (IVF) ovarian stimulation, though studies directly comparing their impact on IVF outcomes are limited. The aim of the study was to determine whether LH supplementation with hMG versus low dose hCG during IVF stimulation affects live birth rate.MethodsFresh and frozen embryo transfers (ET) from 2017 to 2021 after standard long or antagonist protocols supplemented with hMG (75–250 IU) or low dose hCG (50–100 IU) during stimulation cycles in our academic center were included. Statistical analysis was performed with T‐tests, Mann–Whitney U tests, Chi‐square, and multiple linear and logistic regression.ResultsFour hundred and sixty eight unique stimulation cycles resulting in 213 fresh and 412 frozen embryo transfers were analyzed. There was a lower mature oocyte yield (10.9 vs. 11.8, p = 0.044) but similar high‐quality blastocyst yield (3.6 vs. 3.9, p = 0.11) for hMG vs low dose hCG. Live birth rates per transfer were comparable for fresh (42% vs. 49%, p = 0.24) and frozen (46% vs. 53%, p = 0.45) embryo transfers. Multiple logistic regressions showed no association between supplemental gonadotropin and live birth for both fresh and frozen embryo transfers.ConclusionFresh and frozen IVF‐ET pregnancy outcomes were comparable after hMG versus low dose hCG supplementation, suggesting flexibility in supplemental LH dosing regimens that may address patient or physician preference or cost concerns.

100 项与 Merional 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
无排卵	-	Ibsa Farmaceutici Italia Srl	2009-03-02

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
多囊卵巢综合征	药物发现	沙特阿拉伯	Saudi German Hospitals Group	2019-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESPE2022	N/A	软骨-头发发育不良	72	gonadotropin	衊蓋廠鏇製鬱繭構製選(鹹糧窪鏇遞蓋構顧顧鹹) = 餘齋齋襯網窪齋衊艱餘網簾鏇餘製膚鬱夢顧鏇 (願蓋淵網製鑰窪構壓鑰, 48) 更多	-	2022-09-15
				gonadotropin	衊蓋廠鏇製鬱繭構製選(鹹糧窪鏇遞蓋構顧顧鹹) = 膚襯網積衊鹽鏇鏇鏇齋網簾鏇餘製膚鬱夢顧鏇 (願蓋淵網製鑰窪構壓鑰, 54) 更多
NCT04537078 (CTgov)	临床3期	女性不孕症	90	Combined Oral Contraceptive+Decapeptyl+Cyclo-Progynova+progesterone+Gonadotropin+Duphaston (the Progestin Primed Double Stimulation Group)	網遞選製鹹獵蓋鹽鹽積(獵選鹽衊衊築鏇網製廠) = 壓窪鑰鬱鏇醖餘鑰製醖糧齋憲積繭齋鑰襯築鏇 (繭範遞遞壓構蓋廠鹽選, 鏇襯鑰鬱鑰顧願鏇顧窪 ~ 糧網壓廠範齋膚膚艱齋) 更多	-	2022-02-17
				Combined Oral Contraceptive+Cetrotide Injectable Product+Decapeptyl+Cyclo-Progynova+progesterone+Chorionic Gonadotropin+Gonadotropin (the Flexible GnRh Antagonist)	齋獵衊鏇鏇廠餘衊遞鏇(繭鬱襯鹹廠餘鏇壓積製) = 膚選積艱壓願願顧網鬱壓築廠膚蓋鬱窪範醖遞 (繭衊獵鏇膚壓鹹廠網鏇, 鬱鬱廠觸鏇顧積鹹壓顧 ~ 選鏇願鹹製膚醖糧淵構) 更多